Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Novel Clinical Research (India) Private Limited, was an unlisted private company incorporated on 06 December, 2012. It is classified as a private subsidiary of a foreign company and is located in , Karnataka. It's authorized share capital was INR 5.00 lac and the total paid-up capital was INR 1.00 lac.
The current status of Novel Clinical Research (India) Private Limited is - Strike Off.
Read more
Buy Dashboard using Credits
** All rupee values in INR crores. Based on March 2024 numbers.
8.9%
7.69%
-68.97%
2.15%
6.23%
5.07%
5.57
-0.31
-8.37
-8.01
-0.76
0.01
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|---|---|
| Karnataka | Registered Office | 854/1, PP Industrial Area, Mysore Road, Deepanjali Nagar Bangalore Bangalore Karnataka - 560026 |
Locations on Map
Filter (4)
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Sunil Makharia | 00064399 | 9 years |
| Director | Nilesh Deshbandhu Gupta | 01734642 | 9 years |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
As per information available, the company has no registered charges.
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| ZYMA LABORATORIES LIMITED |
Amalgamated
|
1.4 Cr | 2 | Maharashtra |
| ORGO MERCANTILE TRADERS PRIVATE LIMITED |
Amalgamated
|
1.0 L | 2 | Maharashtra |
| D. B. ESTATE TRADE PRIVATE LIMITED |
Amalgamated
|
1.0 L | 2 | Maharashtra |
| RAHAS MULTITRADE PRIVATE LIMITED |
Amalgamated
|
1.0 L | 2 | Maharashtra |
| BS MERC PRIVATE LIMITED |
Amalgamated
|
1.0 L | 2 | Maharashtra |
| ZYMA PROPERTIES PRIVATE LIMITED |
Active
|
1.0 L | 2 | Maharashtra |
| LUPIN HERBAL LIMITED |
Amalgamated
|
5.0 L | 1 | Maharashtra |
| LUPIN HOLDINGS PRIVATE LIMITED |
Amalgamated
|
13.8 Cr | 1 | Maharashtra |
| NOVAMED INVESTMENTS PRIVATE LIMITED |
Amalgamated
|
9.5 Cr | 1 | Maharashtra |
| LUPIN INTERNATIONAL PRIVATE LIMITED |
Amalgamated
|
5.0 L | 2 | Maharashtra |
| ZUARI LEATHERS PRIVATE LIMITED |
Amalgamated
|
15.5 L | 1 | Maharashtra |
| VISIOMED INVESTMENTS PRIVATE LIMITED |
Amalgamated
|
11.9 Cr | 1 | Maharashtra |
| RAHAS INVESTMENTS PRIVATE LIMITED |
Amalgamated
|
13.8 Cr | 2 | Maharashtra |
| SYNCHEM INVESTMENTS PRIVATE LIMITED |
Amalgamated
|
82.5 Cr | 1 | Maharashtra |
| ELEMENT119 LEASING AND FINANCE PRIVATE LIMITED |
Dissolved
|
2.0 Cr | 2 | Maharashtra |
| SAMIKSH INVESTMENT PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Maharashtra |
| GOODYEAR INVESTMENT P. LTD |
Amalgamated
|
1.0 L | 1 | Maharashtra |
| CROP TECH CHEMICALS (INDIA) PRIVATE LIMITED |
Dissolved
|
1.0 Cr | 1 | Maharashtra |
| LUPIN PROPERTIES LIMITED |
Amalgamated
|
5.2 L | 2 | Maharashtra |
| RAHAS MERCANTILE PRIVATE LIMITED |
Amalgamated
|
108.0 Cr | 2 | Maharashtra |
| SYNCHEM PROPERTIES PRIVATE LIMITED |
Active
|
11.0 Cr | 2 | Maharashtra |
| VISIOMED INVESTMENTS PRIVATE LIMITED |
Active
|
5.0 Cr | 2 | Maharashtra |
| LUPIN ATHARV ABILITY LIMITED |
Active
|
10.0 L | 2 | Maharashtra |
| LUPIN INVESTMENTS PRIVATE LIMITED |
Active
|
1.0 L | 2 | Maharashtra |
| POLYNOVA INDUSTRIES LIMITED |
Active
|
23.0 Cr | 2 | Maharashtra |
| LUPIN DIGITAL HEALTH LIMITED |
Active
|
62.3 Cr | 2 | Maharashtra |
| LUPIN DIAGNOSTICS LIMITED |
Active
|
202.6 Cr | 2 | Maharashtra |
| NOVODIGM LIMITED |
Amalgamated
|
2.4 Cr | 1 | Gujarat |
| LUPIN PHARMACARE LIMITED |
Amalgamated
|
1.1 Cr | 1 | Maharashtra |
| LUPIN BIOLOGICS LIMITED |
Active
|
15.0 L | 1 | Maharashtra |
| LUPIN MANUFACTURING SOLUTIONS LIMITED |
Active
|
10.0 L | 1 | Maharashtra |
| LUPIN LIMITED |
Active
|
91.2 Cr | 1 | Maharashtra |
Severe Risk
Moderate Risk
Low Risk
Read more
The incorporation date of NOVEL CLINICAL RESEARCH (INDIA) PRIVATE LIMITED is 06 December, 2012
The authorized share capital of NOVEL CLINICAL RESEARCH (INDIA) PRIVATE LIMITED is INR ₹ 5.0 L.
The paid-up capital of NOVEL CLINICAL RESEARCH (INDIA) PRIVATE LIMITED is INR ₹ 1.0 L.
The registered address of NOVEL CLINICAL RESEARCH (INDIA) PRIVATE LIMITED is 854/1, PP Industrial Area, Mysore Road, Deepanjali Nagar Bangalore Bangalore Karnataka - 560026
The CIN number of NOVEL CLINICAL RESEARCH (INDIA) PRIVATE LIMITED is U73100KA2012FTC067065.
Expand
Delete
Collapse
See
details
